Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
Launched by SUN YAT-SEN UNIVERSITY · May 14, 2012
Trial Information
Current as of September 01, 2025
Unknown status
Keywords
ClinConnect Summary
For HBeAg positive hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In our study, patients without HBeAg loss to 48 weeks entecavir treatment were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 50 years old
- • HBsAg(+) and HBeAg(+) for over 6 months before entecavir treatment
- • Treated by entacavir for 48 weeks with HBeAg seroconversion
- Exclusion Criteria:
- • Pregnant women
- • Decompensated liver disease
- • Combination infection of HCV, HAV, or HEV
- • Combination infection of HIV
- • Any contraindication of interferon α
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Zhiliang Gao
Principal Investigator
The Third Affliated Hospital of Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials